Insmed reports second-quarter 2024 financial results and provides business update

—arikayce® (amikacin liposome inhalation suspension) total revenue of $90.3 million for the second quarter of 2024, reflecting 17% growth over the second quarter of 2023— —u.s. launch readiness for brensocatib in bronchiectasis remains on track with nda submission expected in the fourth quarter of 2024— —primary endpoint for encore study of arikayce in patients with newly diagnosed or recurrent mac lung infection agreed upon with u.s. fda— —company reiterates 2024 global arikayce revenue guidance in the range of $340 million to $360 million, reflecting double-digit growth compared to 2023— bridgewater, n.j. , aug. 8, 2024 /prnewswire/ -- insmed incorporated (nasdaq: insm), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the second quarter ended june 30, 2024, and provided a business update.
INSM Ratings Summary
INSM Quant Ranking